SAN DIEGO, CA – Researchers from the Abramson Cancer Center (ACC) of the University of Pennsylvania and Penn’s Perelman School of Medicine will present data on the latest advances in cancer science and medicine at the American Association for Cancer Research (AACR) Annual Meeting 2026 , taking place April 17-22 in San Diego, CA. Follow Penn Medicine on LinkedIn , Threads , and X for updates from the meeting.
During the meeting, ACC Director Robert Vonderheide, MD, DPhil , will become 2026-2027 President-Elect of AACR, following the association’s annual leadership elections, in which E. John Wherry, PhD , the Barbara and Richard Schiffrin President’s Distinguished Professor and chair of the Department of Systems Pharmacology & Translational Therapeutics, was also elected to serve on the AACR Board of Directors for the 2026-2029 term.
In the Opening Plenary Session , CAR T cell therapy pioneer Carl June, MD , the Richard W. Vague Professor in Immunotherapy, will share progress in developing CAR T cell therapies for solid tumors. June directs the Center for Cellular Immunotherapies at Penn, where researchers continue to advance new and improved CAR T cell therapies , including next-generation “armored” treatments and a dual-target CAR designed for the deadly brain cancer glioblastoma.
The Clinical Trials Plenary 3 Session will feature the first clinical data from the STAR-101 Phase 1 Clinical Trial for patients with advanced ovarian cancer, mesothelioma or cholangiocarcinoma. The study uses a multi-chain CAR T cell therapy called KIR-CAR, which is based on natural killer (NK) cell receptors to overcome T cell exhaustion. Results will be shared by the clinical trial’s principal investigator Janos L. Tanyi, MD, PhD , an associate professor of Obstetrics and Gynecology.
In the Late-Breaking Minisymposium , Hematology-Oncology Fellow Minh Than, MD, PhD, will expand upon work recently published in Science , which showed that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors.
Other invited talks from Penn Medicine experts will focus on some of the biggest topics in cancer prevention, immunotherapy, and discovery science:
Immune evasion and dysregulation: Wherry is chairing and speaking in Major Symposium SY14 - Mechanisms of Immune Evasion and Immune Dysregulation , which will cover potential targets and approaches to improve tumor immunity through immunotherapy and other approaches. Wherry’s research focuses on T cell exhaustion, cancer immunotherapy, and immune health.
AI and tumor mapping: Mingyao Li, PhD , is a professor of Biostatistics and Digital Pathology, whose research focuses on developing machine learning approaches that integrate histology and molecular data to support deeper insights into tissue biology and disease mechanisms. Her work will be featured in Advances in Technologies AT05 - Using AI and Spatial Transcriptomics Data to Predict Spatial Gene Expression from Histopathology Slides .
In Vivo CAR T: Saar Gill, MD, PhD , a professor of Hematology-Oncology, will take part in the AACR-ASCO Joint Session: Next Generation of CAR T-Cell Therapies where he’ll speak about the progress being made to generate CAR T cells directly inside a patient’s body, which would save time and money compared to the current process of engineering CAR T cells for each patient in the laboratory.
At-home cervical cancer testing: Carmen Guerra, MD , the Ruth C. and Raymond G. Perelman Professor of Medicine, is chairing and speaking in Advances in Prevention Research APRV03 - HPV Vaccination and Self-Sampling for Cervical Cancer Prevention and Early Detection Globally and in Underserved Settings . Guerra is involved in community research on self-collection for HPV testing as the Community Outreach and Education leader for the ACC and as the Penn Medicine site lead for the NCI SHIP Trial .
Carman Man-Chung Li, PhD , an assistant professor of Cancer Biology and a core investigator in the Basser Center for BRCA , is the newest recipient of the AACR Gertrude B. Elion Cancer Research Award . The AACR Gertrude B. Elion Cancer Research Award honors Gertrude B. Elion for her groundbreaking work in biochemistry and pharmacology, which transformed cancer treatment and earned her the 1988 Nobel Prize in Physiology or Medicine. This award supports early-stage investigators conducting innovative basic, translational, or clinical cancer research. Li’s presentation will focus on uncovering the earliest processes fueling an aggressive form of breast cancer.
Amulya Sreekumar, PhD, a research associate in Cancer Biology, is one of AACR’s 2026 NextGen Stars , a program that provides graduate students, postdocs, and assistant professors with high-profile presentation opportunities to share highly significant scientific findings with the AACR Annual Meeting audience. Her research into how leftover breast cancer cells maintain a “dormant” state after cancer treatment will be part of the Advances in Understanding Disseminated Tumor Cells Session chaired by her PI Lewis Chodosh, MD, PhD , chair of Cancer Biology. As part of the same session, Chodosh will share his research on preventing breast cancer recurrence by targeting disseminated tumor cells, which was recently translated to a phase II clinical trial .
Experts from the Perelman School of Medicine are available to comment on a wide range of topics in cancer science and medicine during the meeting on site and by video call, telephone, or email. To arrange interviews, please contact Meagan Raeke at Meagan.Raeke@pennmedicine.upenn.edu or 267-693-6224.
###
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine , founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $580 million awarded in the 2023 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Doylestown Health, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.9 billion enterprise powered by more than 50,000 talented faculty and staff.